MHLW Relied On EU and U.S. For Actos Safety Data, But Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance
This article was originally published in PharmAsia News
TOKYO - Japan's Ministry of Health, Labor and Welfare followed the lead of EMA and U.S. FDA and requested Takeda Pharmaceutical Co. Ltd. to change labeling for Actos (pioglitazone) to reflect safety concerns about the risk of bladder cancer. MHLW had to rely on epidemiological data compiled by EMA, but MHLW's safety division hopes new funding from the government will help build an electronic health records database to conduct similar pharmacovigilance epidemiology studies for the Japanese market
You may also be interested in...
In an effort to curb soaring medical costs for social services, Prime Minister Shinzo Abe's growth strategy has included plans to use big data for preventative health care.
Companies like Merck Serono, AstraZeneca and Eisai are reshuffling R&D operations in Asia to capitalize on new hubs of innovation.
Substantial patent expirations in the next few years and government incentives for generic use make Japan's generic market ideal for midterm growth, but stringent API standards and complex distribution channels have left some foreign firms in a difficult spot.